ENETS Abstract Search

Transarterial chemoembolization (TACE) of liver metastasis from pancreatic well-differentiated endocrine carcinoma

#116

Introduction: The behavior of liver metastasis from endocrine pancreatic carcinoma is eterogeneous, and several treatments have been proposed, but no single option is ideal.

Aim(s): To evaluate the efficacy of hepatic transarterial chemoembolization (TACE) in controlling the growth of liver metastasis from pancreatic well-differentiated endocrine carcinoma (WDEC), the safety of the procedure and long-term survival.

Materials and methods: From 2004 to 2009 at our institute, 635 sessions of TACE were performed; 44 of them (6.9%) were performed in 11 patients (mean of four sessions for a patient) for the treatment of liver metastasis from pancreatic WDEC, out of 37 patients with metastatic WDEC (29.7%) The indication for TACE was the presence of multifocal metastases, with diameter less than 5 cm, without extrahepatic disease. The study group was composed by five females and six males, with a mean age of 57.4 years (range 40-72). Four patients presented with liver metastasis at the time of diagnosis of pancreatic neoplasm, whereas seven developed metastasis during the follow-up (mean 37 months, median 22 months; range 5-77). Ten patients presented bilobar liver metastasis and one patient was affected by unilobar disease; ten patients were affected by non-functioning carcinoma whereas one patient was affected by malignant insulinoma. The TACE was performed with Doxorubicin emulsified in Lipiodol, followed by gelatine sponge particles embolization. Imaging follow-up was performed with unenhanced and contrast-enhanced CT scan at one, three, six months and every six months after TACE. The mean follow-up was 34.1 months (range 12-72).

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Zerbi A

Authors: Capitanio V, Papa M, Zerbi A, Vitali G, De Cobelli F,

Keywords: endocrine tumor, liver metastasis, chemoembolization,

To read the full abstract, please log into your ENETS Member account.